Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences | Poland | about 2 months ago
neuroprotective therapy. The project implementation includes extensive cooperation with research centers in Poland and abroad. The Research Assistant will be responsible for: Development of active nanocarriers
-
to therapy and use the knowledge gained from these studies to develop novel therapies for glioblastoma. To this end, we utilize genome-wide screening to identify molecular modifiers of therapy sensitivity
-
the ambition of developing innovative platforms incorporating therapeutic agents (e.g., nucleic acids, small molecules, peptides), involving mRNA for gene therapy. In the context of this project, the group
-
Practice (GMP) Facility is to manufacture clinical grade stem cell and other cellular therapy products, gene therapy products, pharmaceutical products and formulations for novel or routine patient treatment
-
detection, progression, and therapy; cell and gene therapy and regenerative medicine; cardiovascular biomechanics and mechanobiology; biomaterials and tissue engineering; bioseparations and biomolecular
-
, therapy services, perk box. Terms of Appointment: You must be eligible to work in the UK with a willingness to travel as necessary. We are open to sponsoring employment visas for this role; however
-
clinical research professionals, involving work on investigator-initiated clinical research studies and complex industry-sponsored, first-in-human trials of gene therapies for neurological diseases
-
promotional activities on behalf of the University Where to apply Website https://system.erecruiter.pl/FormTemplates/RecruitmentForm.aspx?WebID=4ca5a3a62… Requirements Research FieldPsychological sciences
-
(advanced cardiac therapies), heart rhythm disorders (arrhythmia), and risk factor reduction. Together our team of physicians, nurse practitioners, registered nurses, licensed vocational nurses, device
-
patients with heart conditions including coronary heart disease, heart valve disease (structural), heart failure (advanced cardiac therapies), heart rhythm disorders (arrhythmia), and risk factor reduction